Alternative antiandrogen therapy with flutamide in patients with castration-resistant prostate cancer: A single center experience

Acta Urologica Japonica

Volumn 57, Issue 6, 2011, Pages 291-295

  Takada, Tsuyoshi ^a   Ishizuya, You ^a   Orada, Takayuki ^a   Ueda, Tomohiro ^a   Inoue, Hitoshi ^a   Hara, Tsunco ^a  

^a Ikeda Municipal Hospital   (Japan)

Author keywords

Alternative antiandrogen therapy; Castration resistant prostate cancer; Flutamide

Indexed keywords

ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; FLUTAMIDE; NITRILE; PROSTATE SPECIFIC ANTIGEN; TOLUENESULFONIC ACID DERIVATIVE;

AGED; ARTICLE; CASTRATION; HUMAN; MALE; MIDDLE AGED; NEOPLASM; PROSTATE TUMOR; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS; CASTRATION; FLUTAMIDE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 79961096930     PISSN: 00181994     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Scher HI, Lucbertz C, Kelly WK, et al.: Bicalutamidc for advanced prostate cancer : the natural versus treated history of disease. J Clin Oncol 15 : 2928-2938, 1997 (Pubitemid 27330021)
2. Scher HI, Zhang ZF, Nanus D, et al.: Hormone and antihormonc withdrawal : implications for the management of androgcn-indcpcndcnt prostate cancer. Urology 47: 61-69, 1996 (Pubitemid 126691288)
3. Lam JS, Leppert JT, Vemulapalli SN, et al.: Secondary hormonal therapy for advanced prostate cancer. J Urol 175 : 27-34, 2006 (Pubitemid 41797079)
4. Scher HI, Steineck G and Kelly WK: Hormonerefractory (D3) prostate cancer : refining the concept. Urology 46: 142-148, 1995
5. Joyce R, Fenton MA, Robe P, et al.: High dose BCL for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 159 : 149-153, 1998 (Pubitemid 27525592)
6. Kojima S, Suzuki H, Akakura K, et al.: Alternative antiandrogcns to treat prostate cancer relapse after initial hormone therapy. J Urol 171: 679-683, 2004 (Pubitemid 38090455)
7. Miyakc H, Hara I and Eto H : Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int 96: 791-795, 2005 (Pubitemid 41391382)
8. Nishimura K, Arichi N, Tokugawa S, et al.: Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer. Int J Urol 14 : 264-267, 2007 (Pubitemid 46423250)
9. Okihara K, Ukimura O, Kancmitsu N, et al.: Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after firstline hormonal therapy. Int J Urol 14: 128-132, 2007 (Pubitemid 46121950)
10. Suzuki H, Okihara K, Miyakc H, et al.: Nonsteroidal antiandrogen sequential alternation for prostate cancer study group. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 180: 921-927,2008
11. Maximum androgen blockade 71 : 3-10. 2009
12. Okegawa T, Nutahara K, Higashihara E : Alternative antiandrogen therapy in patients with castrationresistant prostate cancer : a single-center experience. Int J Urol 17:950-955, 2010
13. Veldscholte J, Bcrrevoets CA, Brinkmann AO, et al.: Anti-androgens and the mutated androgen receptor of LNCaP cells : differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 31: 2393-2399, 1992
14. Gaddipati JP, MeLeod DG, Heidenberg HB, et al.: Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54: 2861-2864, 1994
15. Fenton MA, Shuster TD, Fertig AM, et al.: Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 3: 1383-1388, 1997 (Pubitemid 27362400)
16. Taplin ME, Buglcy GJ, Shustcr TD, et al.: Mutation of the androgen-receptor gene in metastatic androgenindependent prostate cancer. N Engl J Med 332 : 1393-1398, 1995
17. Suzuki H, Akakura K, Komiya A, et al.: Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 29 : 153-158, 1996 (Pubitemid 26341820)
18. Hara T, Miyazaki J, Araki H, et al.: Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63 : 149-153, 2003 (Pubitemid 36070433)
19. Haapala K, Hyytincn ER, Roiha M, et al.: Androgen receptor alternations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Invest 81: 1647-1651, 2001 (Pubitemid 33144427)
20. Taplin ME, Rajeshkumar B, Halabi S, et al.: Androgen receptor mutations in androgen-independent prostate cancer : Cancer and Leukemia Group B study 9663. J Clin Oncol 21: 2673-2678, 2003 (Pubitemid 46606310)
21. Klotz L : Combined androgen blockade in prostate cancer : meta-analyses and associated issues. BJU Int 87: 806-813, 2001